Aziz Mottiwala - Mar 8, 2023 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Role
Chief Commercial Officer
Signature
s/ Leonard M. Greenstein, Attorney-in-Fact
Stock symbol
TARS
Transactions as of
Mar 8, 2023
Transactions value $
$0
Form type
4
Date filed
3/10/2023, 06:25 PM
Previous filing
Nov 17, 2022
Next filing
Mar 17, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TARS Stock Option (right to buy) Award $0 +48.1K $0.00 48.1K Mar 8, 2023 Common Stock 48.1K $15.00 Direct F1
transaction TARS Restricted Stock Units Award $0 +32.6K $0.00 32.6K Mar 8, 2023 Common Stock 32.6K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the option shares shall vest on March 8, 2024, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years subject to the Reporting Person's continuous service.
F2 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.
F3 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026, and 2027, subject to the Reporting Person's continuous service.